PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22155740-9	2012	RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta.	parthenolide	27-39	tumor necrosis factor	Mus musculus	344-353	
21719790-7	2011	Furthermore, inhibition of NFkappaB with parthenolide prevented TWEAK- or TNFalpha-induced downregulation of Klotho.	parthenolide	41-53	tumor necrosis factor	Mus musculus	74-82	
16223857-6	2006	Palmitate increased nuclear factor (NF)-kappaB activation and incubation of the cells with the NF-kappaB inhibitors pyrrolidine dithiocarbamate and parthenolide partially prevented TNF-alpha expression.	parthenolide	148-160	tumor necrosis factor	Mus musculus	181-190	
32373209-11	2020	PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue.	parthenolide	0-3	tumor necrosis factor	Mus musculus	88-97	
27997959-8	2017	The results suggested that parthenolide may regulate the activity of Th17 and Th1 cells, mainly by decreasing IL-17, TNF-alpha, and interferon gamma production.	parthenolide	27-39	tumor necrosis factor	Mus musculus	117-126	
23066037-7	2013	Parthenolide has an anti-inflammatory activity and suppressed NF-kappaB activity by inhibition of IkappaBalpha phosphorylation after TNF-alpha stimulation and strongly inhibited TNF-alpha-induced VCAM-1 expression on MSCs.	parthenolide	0-12	tumor necrosis factor	Mus musculus	133-142	
23066037-7	2013	Parthenolide has an anti-inflammatory activity and suppressed NF-kappaB activity by inhibition of IkappaBalpha phosphorylation after TNF-alpha stimulation and strongly inhibited TNF-alpha-induced VCAM-1 expression on MSCs.	parthenolide	0-12	tumor necrosis factor	Mus musculus	178-187	
17349210-7	2007	Inhibition of NF-kappaB transactivation by inhibitors, BAY 11-7085 and parthenolide, reversed the suppression of Fas-mediated apoptosis by TNF-alpha.	parthenolide	71-83	tumor necrosis factor	Mus musculus	139-148	
16783963-3	2006	In this study we investigated the molecular pathway involved, and showed that the addition of NF-kappaB inhibitors salicylate and parthenolide reduced the levels of TNF secreted into the culture supernatants induced with DMXAA (10 microg/ml) alone or in combination with LPS (10 microg/ml).	parthenolide	130-142	tumor necrosis factor	Mus musculus	165-168	
15987517-4	2005	The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels.	parthenolide	60-72	tumor necrosis factor	Mus musculus	143-176	
12504894-15	2003	Furthermore, the NFkappaB inhibitor parthenolide suppressed MGO-BSA-induced TNFalpha secretion.	parthenolide	36-48	tumor necrosis factor	Mus musculus	76-84	
31018556-5	2019	Parthenolide, a pan-inflammation inhibitor, reversed the PAH-induced inhibition of GJIC, the decreased CX43 expression, and the induction of KC and TNF.	parthenolide	0-12	tumor necrosis factor	Mus musculus	148-151	
27270078-7	2016	Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro.	parthenolide	13-25	tumor necrosis factor	Mus musculus	117-126